Insider · CIK 0001458494
Akshay Vaishnaw
Files at SRRK (Scholar Rock Holding Corp). First filing May 30, 2025, latest Apr 20, 2026.
In brief
Akshay Vaishnaw files SEC Form 4 as president and director at SRRK (Scholar Rock Holding Corp). Since May 30, 2025, Akshay Vaishnaw has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.7M, the latest filed on Apr 20, 2026.
A track record needs three past buys with six months of prices behind them; Akshay Vaishnaw has 0, so none is measured yet.
The newest scored trade: sold $607k of SRRK on Apr 16, 2026, filed Apr 20, 2026, scored 54 (moderate). In the last 12 months: 0 buys worth $0 and 2 sells worth $1.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SRRK: Scholar Rock Holding Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | Scholar Rock Holding Corp | $607k 12,246 shares | -2% | +79% from low-0% from high | |
| 58Moderate | Scholar Rock Holding Corp | $873k 20,438 shares | -3% | +79% from low-7% from high | |
| 27Weak | Scholar Rock Holding Corp | $201k 6,750 shares | -1% | +322% from low-36% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 29, 2025 | SRRK Scholar Rock Holding Corp. | 6,750 0.01% of outstanding | $200k | May 29, 2025 | none |
| Dec 11, 2023 | ALNY ALNYLAM PHARMACEUTICALS, INC. | 10,832 0.01% of outstanding | $1.8M | Dec 11, 2023 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | SRRK Scholar Rock Holding Corp | SOpen-market sale Common Stock | -12,246 | $49.57 | $607k | 630,542 | Apr 20, 2026 |
| Feb 9, 2026 | SRRK Scholar Rock Holding Corp | AGrant or award Common Stock | +47,021 | $0.00 | $0 | 642,788 | Feb 11, 2026 |
| Jan 13, 2026 | SRRK Scholar Rock Holding Corp | SOpen-market sale Common Stock | -20,438 | $42.70 | $873k | 595,767 | Jan 15, 2026 |
| May 29, 2025 | SRRK Scholar Rock Holding Corp | SOpen-market sale Common Stock10b5-1 | -5,130 | $29.63 | $152k | 617,825 | May 30, 2025 |
| May 29, 2025 | SRRK Scholar Rock Holding Corp | SOpen-market sale Common Stock10b5-1 | -1,620 | $30.01 | $49k | 616,205 | May 30, 2025 |
| May 2, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Stock Option (Right to Buy)derivative | +110,067 | $0.00 | $0 | 110,067 | May 6, 2025 |
| Apr 27, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 122,955 | Apr 29, 2025 |
| Apr 27, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 622,955 | Apr 29, 2025 |
Questions about Akshay Vaishnaw
Answered from the filings on this page, as of the latest one.
Is Akshay Vaishnaw buying or selling?
In the last 12 months Akshay Vaishnaw reported 0 open-market buys worth $0 and 2 open-market sells worth $1.5M on SEC Form 4; the latest was sold $607k of SRRK on Apr 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Akshay Vaishnaw's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Akshay Vaishnaw has 0.
Where does Akshay Vaishnaw file Form 4?
Akshay Vaishnaw has filed Form 4 at SRRK (Scholar Rock Holding Corp) as President of R&D. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.